|Articles|October 15, 2001
- BioPharm International-10-01-2001
- Volume 14
- Issue 10
Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing: Part 1, Considerations for Technology Transfer and Commercial Development
Author(s)Steven Ford, William E. Tente
by Steven Ford and William E. Tente Chimeric Therapies, Inc. Manufacturing processes for murine monoclonal antibodies (mMABs) used in therapeutic applications must address more safety concerns than those used for in vitro diagnostics. Adequate characterization helps ensure that the mMAb retains its functional integrity after more extensive processing.
Advertisement
Articles in this issue
almost 24 years ago
Qualification of Network Components and Validation of Networked Systemsalmost 24 years ago
Statistical Tools for Setting In-Process Acceptance Criteriaalmost 24 years ago
Managing Your Career: Recruiter-Proof Your Organizationalmost 24 years ago
Inside Washington: Crisis and Costs Grip Biotech Industryalmost 24 years ago
Outsourcing OutlookNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
